01
5% coupon
Your own code on signup. Applied when you are signed in.
Shop by category
Wholesale / Weight loss / Fitaro Semaglutide Injection physiological regulator of appetite and caloric intake
Semaglutide is a GLP-1 analogue with 94% sequence as same as human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that
selectively binds to and activates the GLP- receptor. GLP-1 is a physiological regulator of appetite and caloric intake. It is also present
in several areas of brain that involved in appetite regulation. Semaglutide lowers body weight through decreased calorie intake and by
an overall reduced appetite. It also stimulates insulin secretion and reduces glucagon secretion in a glucose dependent manner.
Select the option you require — the selected option is included in your inquiry.
Fitaro Semaglutide Injection physiological regulator of appetite and caloric intake is a weight-loss injection from Fitaro, listed for registered Australian clinics in our Weight loss range. Pack: see product images for pack format. Priced in AUD (A$171.00). Sydney dispatch, nationwide. Not a public treatment clinic.
Fitaro 0.25 mg injection: Each pre-filled syringe contains Semaglutide INN 0.25 mg in 0.5 ml solution for injection.
Fitaro 0.50 mg injection: Each pre-filled syringe contains Semaglutide INN 0.50 mg in 0.5 ml solution for injection.
Fitaro 1 mg injection: Each pre-filled syringe contains Semaglutide INN 1 mg in 0.5 ml solution for injection.
Fitaro 1.7 mg injection: Each pre-filled syringe contains Semaglutide INN 1.7 mg in 0.75 ml solution for injection.
Fitaro 2.4 mg injection: Each pre-filled syringe contains Semaglutide INN 2.4 mg in 0.75 ml solution for injection.
Semaglutide is a GLP-1 analogue with 94% sequence as same as human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that
selectively binds to and activates the GLP- receptor. GLP-1 is a physiological regulator of appetite and caloric intake. It is also present
in several areas of brain that involved in appetite regulation. Semaglutide lowers body weight through decreased calorie intake and by
an overall reduced appetite. It also stimulates insulin secretion and reduces glucagon secretion in a glucose dependent manner.
An adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body
mass index (BMI) of :
• 30 kg/m2 or greater (Obesity) or
• 27 kg/m2 or greater (Overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes
mellitus or dyslipidemia).
The starting dose is 0.25 mg Semaglutide once weekly for 4 weeks subcutaneously. Then in 4 weeks intervals dose should be
increased until a dose of 2.4 mg is reached. Patient should follow the dose escalation schedule given below.
| Weeks | Weekly Dose | Dose Escalation |
| 1 through 4 | 0.25 mg | |
| 5 through 8 | 0.5 mg | |
| 9 through 12 | 1 mg | |
| 13 through 16 | 1.7 mg | |
| Week 17 and onwards | 2.4 mg | Maintenance dose |
If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks. If patients do not tolerate the
maintenance dose 2.4 mg , the dose can be temporarily decreased to 1.7 mg once weekly for maximum 4 weeks. After 4 weeks
increase the dose to 2.4 mg. Semaglutide is to be administered once weekly at any time of the day with or without meals. Semaglutide
is to be injected subcutaneously in the abdomen, thigh or in upper arm.
If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer Semaglutide as soon as possible. If
one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on
the regular scheduled day of the week.
Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia Syndrome type 2.
Hypersensitivity to the active substance or to any of the excipients.
Pancreatitis: Semaglutide should be discontinued promptly if pancreatitis is suspected and it should not be restart if pancreatitis is
confirmed.
Acute Gallbladder Disease: If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
Hypoglycemia: Concomitant use with an insulin secretagogues or insulin may increase the risk of hypoglycemia. Reducing the dose of
insulin secretagogue or insulin may be necessary.
Diabetic Retinopathy: Patient with diabetic retinopathy should be monitored.
Heart Rate: Heart rate should be monitor at regular intervals.
Suicidal behavior and Ideation: Monitor should be done for depression or suicidal thoughts. If symptoms develop, semaglutide should
be discontinued.
The most common adverse reactions are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia,
dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and
gastroesophageal reflux disease.
Semaglutide lowers blood glucose and can cause hypoglycemia. The risk of hypoglycemia is increased when it is used in combination
with insulin secretagogues (sulfonylureas) or insulin. So when initiating Semaglutide, the dose of concomitantly administered insulin
secretagogue (sulfonylureas) or insulin should be reduce.
Elderly: No dose adjustment is required based on age.
Renal impairment: No dose adjustment is required for patients with mild moderate or severe renal impairment.
Hepatic impairment: No dose adjustment is required for patients with hepatic impairment.
Semaglutide should not be used during pregnancy. If a patient wishes to become pregnant Semaglutide should be discontinued at least
2 months before a planned pregnancy. As a risk to a breast-fed child cannot be excluded, Semaglutide should not be used during
breast-feeding.
Paediatric population: The safety and efficacy of Semaglutide in children and adolescents below 18 years have not yet been
established. No data are available.
The most commonly reported adverse reaction was nausea, vomiting and hypoglycemia. All patients recovered without complications.
In the event of overdose appropriate supportive treatment should be initiated according to the patients clinical sign and symptoms.
Store at 2 C to 8 C (in a refrigerator). Do not freeze. Keep out of reach of children.
Semaglutide is a GLP-1 analogue with 94% sequence as same as human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that
selectively binds to and activates the GLP- receptor. GLP-1 is a physiological regulator of appetite and caloric intake. It is also present
in several areas of brain that involved in appetite regulation. Semaglutide lowers body weight through decreased calorie intake and by
an overall reduced appetite. It also stimulates insulin secretion and reduces glucagon secretion in a glucose dependent manner.
Weight-loss injections differ by active ingredient, dose step and pen format. Check the strength and dose schedule on this page against the prescribing protocol you follow, store pens as the manufacturer directs, and confirm the quantity needed for a full treatment period before ordering.
Compare Fitaro Semaglutide Injection physiological regulator of appetite and caloric intake with Saxenda injector pen, Tizaro Tirzepatide 2.5mg/5mg/7.5mg control high blood sugar, Mounjaro 2.5mg/5mg 1pen (4 dosen) Tirzepatide, or browse the full Weight loss catalogue. Clinics ordering in volume can use our wholesale enquiry program (AUD $5,000 minimum). See also the clinic FAQ and delivery information. Active-ingredient background for Fitaro Semaglutide Injection physiological regulator of appetite and caloric intake is covered in the reference article on Semaglutide, and Australian practitioners should confirm regulatory positionings with the TGA before use.
Wholesale pricing is provided by our team after review of your inquiry. Prices are not displayed in this section.
Member desk
Practitioners who create a free account get an automatic 5% coupon at checkout, the PBF1800 fill ($2,000 cart billed at $1,800 + free delivery), and 25% off + free delivery on orders of $5,000+. Saved cart, past orders, and promotions live in your Account. Ordering as a guest still works — the codes do not.
01
Your own code on signup. Applied when you are signed in.
02
$2,000 → $1,800 + free delivery.
03
25% off and free delivery, applied automatically.
Why clinics choose us
One Sydney desk for fillers, threads, boosters, meso, toxins, vitamins, cosmetics, equipment and clinic consumables — the families Australian rooms actually order.
We list professional-grade lines and expect you to work from IFUs, training and your own clinical judgement. We do not claim products are free of allergy or side effects.
Direct supply keeps clinic pricing competitive. Built for treatment menus and wholesale reorders — not flash consumer sales.
Verified high-use clinics can request volume terms after confirmation — built for practices, not flash consumer sales.
Packed from NSW with cold-chain where required. Inner-city weekday runs, interstate insulated freight, and international courier (including EMS / FedEx) when we confirm the route. Delivery details.
Questions about stock, categories or an order go to info@premiumbeautyfillers.com, WhatsApp or live chat. See FAQ or Contact. We reply in Sydney business hours.